A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The purpose of the study is to examine both efficacy of LBH589 in treating relapsed and refractory DLBCL, and added benefit of combining rituximab with LBH589 in this setting. Tissue samples from accessible lymph nodes will be collected and banked before the start of the study treatment and after 15 days. Additionally, blood samples will be drawn and stored in the tissue biobank.
Epistemonikos ID: 5a023cf08befadb01808dbbcf080175e0b7d2c2b
First added on: May 06, 2024